A PHARMACOLOGICAL COMPARATIVE STUDY OF ARFORMOTEROL AND SALBUTAMOL NEBULIZATION IN THE MANAGEMENT OF PATIENTS SUFFERING FROM ACUTE NON-SEVERE BRONCHIAL ASTHMA

Nusrat Nabi¹, Rishika Agarwal², Himika Mukhopadhyay³, Hajra Banoo⁴, M. K. Meghwani⁵, Nilam Nigam⁶, Niraj Nigam⁷

¹Assistant Professor, Department of Pharmacology, Rama Medical College Hospital & Research Centre, Kanpur.  
²Tutor, Department of Pharmacology, Rama Medical College Hospital & Research Centre, Kanpur.  
³Tutor, Department of Pathology, Rama Medical College Hospital & Research Centre, Kanpur.  
⁴Professor and Head, Department of Physiology, Rama Medical College Hospital & Research Centre, Kanpur.  
⁵Professor, Department of T.B & Chest Medicine, Rama Medical College Hospital & Research Centre, Kanpur.  
⁶Professor and Head, Department of Pharmacology, Rama Medical College Hospital & Research Centre, Kanpur.  
⁷MSc. Student, Department of Pharmacology, Rama Medical College Hospital & Research Centre, Kanpur.

ABSTRACT

BACKGROUND

Arformoterol, is a long-acting beta-2 (β-2) agonist which has a rapid onset and long duration of action. Not many studies in clinical setup have been done to analyse its role in acute attack of asthma.

OBJECTIVES: This study was planned to compare the efficacy and tolerability of monotherapy with arformoterol with salbutamol nebulization, in management of patients with acute non-severe asthma.

MATERIALS AND METHODS

A total of 60 patients of acute non-severe bronchial asthma were randomized into two groups in 1:1 ratio, to either receive three doses of salbutamol (5 mg) or arformoterol (15 μg) nebulization, at 20 minutes intervals. The baseline characteristics of the subjects were measured at the baseline, which were comparable between the two groups and thus adequately matched. The primary outcome of the study was the measure of change in peak expiratory flow rate (PEFR); which was measured at the baseline and 5 minutes after each dose. All the emergent adverse events were also recorded.

Setting and Design - A prospective randomized parallel group, single blind, active control study; carried out in a tertiary care teaching hospital.

RESULTS

The results of this study reflected a significant increase in the mean PEFR in both the groups as compared with the baseline. However, the increase in the PEFR in two groups was comparable after the third dose, with no statistical significance. Both the treatments were well-tolerated with mild adverse effects in both the groups.

CONCLUSION

From the observations made in the study it is concluded that arformoterol is as effective and safe as salbutamol in the management of acute non-severe bronchial asthma.

KEYWORDS

Beta-2 (β-2) Agonist, Bronchial Asthma, Bronchodilator, Peak Expiratory Flow Rate, Randomized Controlled Trial.


BACKGROUND

Asthma is a chronic inflammatory condition that involves hyper responsiveness of tracheobronchial smooth muscles, resulting in potential airway obstruction. The prevalence of asthma is increasing in most of the countries. About 300 million people worldwide have asthma and by 2025 it has been estimated that a further 100 million will be affected.¹ Change in the epidemiology of asthma and its clinical spectrum is another global concern.²

The severity of symptoms and signs of asthma, along with the findings on functional lung assessment, are used to categorize asthma exacerbations as mild, moderate, severe, or life-threatening.³ The clinical diagnosis of asthma can be corroborated by changes in pulmonary function tests.

Beta-2 (β-2) agonists are considered the first line drugs in the treatment of asthma. Short-acting β-2 agonists are the preferred drugs for the initial treatment of acute non-severe asthma because of their rapid onset of action.¹ Long-acting β-2 agonists such as salmeterol and formoterol are important controller medications in the maintenance therapy of chronic stable asthma and are generally used as an add-on drugs to inhaled corticosteroid.⁵ However their usefulness in the management of acute attacks of asthma has recently been recognized⁶ and they are now approved for use as reliever medication in Europe. Formoterol is a unique bronchodilator having rapid onset and long duration of action. Formoterol...
provides an ideal rapid as well as long duration bronchodilatation thereby reducing the need for frequent administration. The onset of action of formoterol is similar to salbutamol (1–3 min)7 with 80–90% of bronchodilatation occurring within 5–10 minutes of inhalation.9 The duration of action is up to 12 hours;9 however, the duration of systemic effects with formoterol is found to be as short as that of salbutamol.10 The safety and tolerability of formoterol is well documented and is considered to be comparable to salbutamol.11 It is therefore an alternative to short-acting β2 agonists in the management of acute asthma exacerbation. Arformoterol ([R, R] Formoterol) is a single isomer of formoterol and the only long-acting β2 agonist available in India as a nebulizing solution; thus, we have used this drug considering the fact that the clinical pharmacology will be similar with formoterol.

Although safety and efficacy of drugs is established prior to marketing, it is important that comparison studies be undertaken by independent groups catering to specific population, to mirror the actual conditions in clinical practice and to assess the evaluating drug further in the post-marketing phase. Besides, there is also dearth of study-literature demonstrating the role of arformoterol nebulization as a rescue medication, in patients with acute non-severe asthma. Hence, the objective of the present study is to compare the efficacy and safety of arformoterol with salbutamol nebulisation, in the management of patients with acute non-severe asthma.

MATERIALS AND METHODS
Source of Data and Population
The present study protocol was approval by the Institutional Ethics Committee (IERB) of Rama medical college hospital and research centre, Kanpur, India and the study was conducted in accordance with the International Conference on Harmonisation – Good Clinical Practice (ICH-GCP) guidelines. A written and signed informed consent was obtained from all the subjects enrolled in the study after the eligibility screening. The study was designed as a single-blind, randomized, controlled trial. The study was carried out on 60 patients of either sex, with acute non-severe asthma; attending the emergency or chest medicine outpatient clinic of a tertiary care hospital in Kanpur, over a period of 4 months, from July 2015 to October 2015. Patients with (a) age > 19 years; (b) British Thoracic Society definition of acute non-severe asthma12 and (c) ability to perform forced expiratory (PEFR) manoeuvre were included in the study. The exclusion criteria were the following: (a) patients presenting with acute severe/acute life-threatening/near-fatal asthma; (b) patients with a previous diagnosis of chronic obstructive pulmonary disease (COPD); (c) smokers (d) history of hypersensitivity to β2 agonists; and (e) pregnant or lactating women.

Demographic and Clinical Characteristics
Age, sex, duration of asthma symptoms and controller medications used by the subjects were recorded. The pulse rate, respiratory rate, and SpO2 (Measured with Nidek Fingertip Pulse Oximeter 6500 model, India) were also recorded at the initial assessment. Anthropometric measurements like height and weight were recorded and BMI calculated. Peak expiratory flow rate (PEFR) was measured by ‘Spiro Exel’ (PC based, computerized software of Pulmonary Function Tests); at baseline and after each study drug dose.

Study Design
The patients were randomized in 1:1 ratio into two study groups, using computer generated random number list; receiving either salbutamol or arformoterol nebulization. Standard marketed brands of both the drugs were used and administered in a single blind manner, with medication identity not being revealed to the patients. In the salbutamol group, 5 mg salbutamol respules were administered through oxygen driven (6 L/min) nebulizer (Pulmo mist II nebuliser, Nidek Medical, India) at 20 minute intervals for 1 hour delivering a total of 15 mg. In the arformoterol group, a total 45 μg of the drug was delivered as 15 μg respules every 20 minutes for 1 hour, through the same nebulizer. Standard marketed brands of both the drugs were used and administered in a single blind manner. Allocation concealment was done by using the serially numbered, opaque, sealed envelope technique. The randomization process and the code breaking authority was given to a senior pharmacologist not interacting with the subjects. Systemic corticosteroids, to be given along with long acting β-agonists (LABA)13 were added only after the administration of third dose of the study drug, to eliminate the effects of other drugs on the treatment outcome.

End-points and Safety Profile
The primary end-point for the evaluation of efficacy of the study drugs was the change in PEFR. PEFR was measured 5 minutes after each dose of the study drug and the mean of the three PEFR measurements was recorded each time. The pulse rate, respiratory rate, and SpO2 were also recorded after each dose delivery. The patients were followed up for the next 6 hours following the third dose. Tolerability was assessed in terms of reported adverse experiences. All the adverse events, reported by the trial subjects were recorded in the structured case report form.

Statistical Analysis
Difference in mean PEFR between the two groups was analyzed by unpaired t-test. PEFR before and after each dose of the drug was also compared to determine whether there was significant improvement within the group by one-sample test. P < 0.05 was considered statistically significant.

RESULTS
A total of sixty patients were enrolled in the study; with 30 patients each in arformoterol and salbutamol group.

From Table 1 it is evident that the baseline characteristics of the two study groups were comparable and thus adequately matched.

Table 2 reflects the improvement in PEFR following the therapy with salbutamol and arformoterol nebulization. In both the groups, PEFR showed significant increase over the baseline values and the increase was evident after each dose of the drug. The increase in PEFR after the first and the second dose was significantly more with arformoterol than with salbutamol, but the increase in PEFR after third dose was similar in both the groups.
Safety Analysis
As depicted in Table 3, both the drugs were well tolerated, no serious adverse events were encountered and all the adverse events (AEs) noted were mild. All the AEs were classified as treatment emergent adverse events (TEAEs) across both studies. The greatest number of subjects reported AEs in the system organ class of central nervous system disorders. In the salbutamol group, out of the 9 patients who experienced adverse effects; 2 complained of headache and 2 patients complained of muscular tremor; whereas, in the arformoterol group, out of the 7 patients with adverse effects; 2 patients complained of headache and 1 complained of tremor. No clinically significant safety findings were observed. Compliance was excellent in both the study groups and none of the patients discontinued the treatment.

<table>
<thead>
<tr>
<th>Parameters (Units)</th>
<th>Salbutamol Group (N = 30)</th>
<th>Arformoterol Group (N = 30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>30.20±5.78</td>
<td>31.60±5.73</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male (%)</td>
<td>56.66 (17)</td>
<td>53.33 (16)</td>
</tr>
<tr>
<td>Female (%)</td>
<td>43.34 (13)</td>
<td>46.67 (14)</td>
</tr>
<tr>
<td>Weight (Kg)</td>
<td>65.29±6.99</td>
<td>67.7±6.18</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>170.3±4.94</td>
<td>173.6±4.17</td>
</tr>
<tr>
<td>Respiratory rate (breaths/min)</td>
<td>18.50±0.92</td>
<td>18.30±1.1</td>
</tr>
<tr>
<td>Pulse rate (beats/min)</td>
<td>95.30±2.41</td>
<td>97.70±2.76</td>
</tr>
<tr>
<td>SpO₂ (%)</td>
<td>97.40±1.28</td>
<td>97.10±1.18</td>
</tr>
<tr>
<td>Symptom duration (years)</td>
<td>5.8±3.15</td>
<td>6.86±3.98</td>
</tr>
</tbody>
</table>

Table 1. Demographic and Baseline Characteristics of the Subjects in the Two Study Groups Comprising of Salbutamol 5 mg (nebulization) and Arformoterol 45 μg (nebulization)

<table>
<thead>
<tr>
<th>PEFR (L/min)</th>
<th>Salbutamol Group (N = 30)</th>
<th>Arformoterol Group (N = 30)</th>
<th>p-value</th>
<th>CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>235.0±3.0</td>
<td>234.50±4.05</td>
<td>&gt;0.05</td>
<td>1.00–2.00</td>
</tr>
<tr>
<td>After first dose, First dose—baseline</td>
<td>269.30±2.84</td>
<td>279.24±4.05</td>
<td>&lt;0.05</td>
<td>8.87–10.72</td>
</tr>
<tr>
<td>After second dose, Second dose—baseline</td>
<td>293.10±4.93</td>
<td>304.40±6.1</td>
<td>&lt;0.05</td>
<td>0.94–13.29</td>
</tr>
<tr>
<td>After third dose, Third dose—baseline</td>
<td>314.90±5.17</td>
<td>320.20±4.57</td>
<td>&gt;0.05</td>
<td>0.973–6.74</td>
</tr>
</tbody>
</table>

Table 2. Descriptive Summary and Statistical Comparison of PEFR in the Salbutamol 5 mg (nebulization) and Arformoterol 45 μg (nebulization) Study Groups

DISCUSSION
Asthma is a disease which besides having a considerable economic burden has physical, emotional and social effects as well; leading to reduced quality of life of patients and their families. The goal of treatment of asthma is to improve patients' quality of life by providing rapid relief of symptoms and reducing the severity and number of recurrent episodes. Although short acting β-2 agonists are used in acute exacerbations of asthma; the usefulness of long acting β-2 agonists has recently been recognized in the management of acute attacks of asthma. Hence, the objective of our study was to compare arformoterol with salbutamol nebulization in the management of acute non severe asthma.

The results of our study reflect that arformoterol is as effective as a reliever medication, as salbutamol, in acute non-severe asthma. Statistically significant improvement in PEFR as compared to the baseline was demonstrated in both the groups. Several studies have shown the efficacy of formoterol in acute non-severe asthma, acute severe asthma, exercise induced bronchospasm, childhood asthma, and COPD. Although few studies have shown clinically significant improvement in lung function (FEV1) with formoterol when compared with salbutamol, most studies have shown a comparable efficacy. Safety of formoterol is also well documented even at high doses in patients with asthma and COPD. Although it is a long-acting drug, systemic effects with formoterol are as short as salbutamol.

Relatively, hydrophilic drugs such as salbutamol have rapid onset of action due to their ability to reach the β2 receptor from the aqueous phase. Formoterol is a moderately lipophilic drug, about 300 times more than salbutamol. The aqueous portion rapidly activates the β2 receptor, whereas the lipophilic portion is taken up into the cell membrane from which it diffuses slowly to stimulate β2 receptor over a prolonged period. This accounts for rapid onset along with long duration of action of formoterol. In this study the increases in PEFR after the first and the second doses were significantly more with arformoterol than with salbutamol; proving that arformoterol has a rapid onset of action.

Both the drugs were well tolerated with no serious adverse events. Very few adverse events were documented which were mild and comparable between these two drugs. Dryness of mouth was the most reported side effect of formoterol inhalation in one study. In our study, the greatest number of AEs were reported in the system organ class of central nervous system disorders, with headache and muscle tremors being the most commonly reported. In few studies, the impact of high-dose formoterol on heart rate,

All parameters are arithmetic mean (standard deviation) SD, standard deviation; N, sample size; CI, confidence interval; p > 0.05 = significant; p < 0.05 = not significant.
blood pressure, serum potassium, electrocardiogram changes, and arterial blood gas were assessed which showed identical changes comparable with salbutamol. However, in our study we only evaluated the adverse effects reported by the patients.

The main limitation of this study was its restriction to patients of acute non-severe asthma only. The efficacy and tolerability of arformoterol in severe asthma and acute exacerbation of COPD are yet to be explored. The objective assessment of adverse effects and laboratory abnormalities were not studied. No arrangement to assess the persistence of adverse events was done as the patients were not followed up after the discharge. Also, as with all single blinded trials, the possibility of bias in subjective assessment by the attending investigator was present in this study as well.

CONCLUSION

From the observations of the present study it can be concluded that arformoterol is comparable in terms of efficacy and safety to salbutamol. However, further studies are thus needed to establish the long-term safety of arformoterol in acute exacerbations of asthma and COPD with different levels of severity, especially in Indian population.

Acknowledgments

We would like to thank Dr. Nasir Nabi Naikoo, postgraduate trainee, department of pathology, for assistance in laboratory investigations; and Mrs. Chitra R Chauhan, statistician, department of community medicine, for assistance in data analysis.

REFERENCES